Rate My Professor Brian Huntly

The Huntly laboratory investigates leukaemia stem cell biology and leukaemogenesis, focusing on how normal haematopoietic stem and progenitor functions are disrupted in the stepwise development of acute myeloid leukaemia and other malignancies like lymphomas, particularly through transcriptional and epigenetic changes. The group integrates functional assays, genomic and proteomic analyses using mouse models, cell lines, and primary human tumour samples to uncover disease mechanisms and therapeutic targets. Seminal publications include Huntly et al. (Cancer Cell, 2004), showing distinct stem and progenitor origins for chronic and acute myeloid leukaemia; Dawson et al. (Nature, 2011), establishing BET inhibitors as therapy for MLL-fusion leukaemia; Horton et al. (Nature Cell Biology, 2017), demonstrating malignant properties in lymphoid progenitors from Crebbp loss; Gozdecka et al. (Nature Genetics, 2018), revealing non-catalytic UTX tumour suppression; Yun et al. (Nature Genetics, 2021), dissecting mutational synergies in leukaemia; Agrawal-Singh et al. (Blood, 2023), identifying the HOXA9 repressive complex; and Lara-Astiaso et al. (Nature Genetics, 2023), characterizing chromatin factor roles in haematopoiesis.